Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.59    -0.31 (-10.69%)
Bid:
2.60
Ask:
2.91
Spread: 0.31 (11.923%)
Market Cap: £4.73m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

PrimaryBid.com Offer

15 Jul 2020 17:20

RNS Number : 1337T
Nanoco Group PLC
15 July 2020
 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 779021)

 

15 July 2020

 

Nanoco Group plc

("Nanoco" or the "Company") (LON:NANO)

PrimaryBid.com Offer

 

Nanoco Group plc (LON:NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, is pleased to announce an offer for subscription via PrimaryBid (the "PrimaryBid Offer") of new ordinary shares of 10p each in the Company ("New Ordinary Shares") at an issue price of 17.5 pence per New Ordinary Share (the "Issue Price"), being a discount of 2.8% per cent to the closing mid-price on 15 July 2020 as announced earlier on 15 July 2020 .

The PrimaryBid Offer is conditional on the new Ordinary Shares to be issued pursuant to the PrimaryBid Offer being admitted to listing on the Official List by the Financial Conduct Authority and to trading by the London Stock Exchange on its main market for listed securities ("Admission"). Admission is expected to be take place at 8.00 a.m. on 20 July 2020.

The net proceeds of the Fundraising will be used to extend the Company's cash runway at least to the end of calendar year 2021 while supporting its core IP assets and its business operations during the ongoing lawsuit against Samsung.

The Company's largest shareholder, Lombard Odier, has undertaken to subscribe for £2.14m of New Ordinary Shares on the same terms as those set out above, which subscription shall be subject to claw back depending on the amount of the other aggregate applications received from other investors under the PrimaryBid Offer. Lombard Odier will receive, conditional upon Admission (as defined below), a subscription commission equal to 3.0 per cent of the amount it subscribes . In the event that Admission does not occur, Lombard Odier will not receive any commission payment. .

Certain directors of the Company and/or persons closely associated with them have given written undertakings to the Company to subscribe for PrimaryBid Shares at the Issue Price with a total value of £61,000.

PrimaryBid Offer

The Company values its retail investor base and is therefore pleased to provide private and other investors the opportunity to participate in the PrimaryBid Offer by applying exclusively through the www.PrimaryBid.com platform and the PrimaryBid mobile app available on the Apple App Store and Google Play. PrimaryBid does not charge investors any commission for this service.

The PrimaryBid Offer, via the PrimaryBid.com platform, will be open to individual and institutional investors immediately following this announcement and will close at 9:00 p.m. on 15 July 2020. The PrimaryBid Offer may close early if it is oversubscribed.

Subscriptions under the PrimaryBid Offer will be considered by the Company on a "first come, first served" basis, subject to conditions (which are available to view on PrimaryBid.com).

The Company in consultation with PrimaryBid reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the Offer without giving any reason for such rejection. It is not intended that the Director orders be subject to scale back.

No commission is charged to investors on applications to participate in the PrimaryBid Offer made through PrimaryBid. It is vital to note that once an application for New Ordinary Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

For further information on PrimaryBid.com or the procedure for applications under the PrimaryBid Offer, visit www.PrimaryBid.com or call PrimaryBid.com on +44 20 3026 4750. 

The New Ordinary Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Company's existing Ordinary Shares.

Nanoco Group PLC

Michael Edelman, CEO

Brian Tenner, COO & CFO

Caroline Watson, Investor Relations Manager

 

+44 (0) 161 603 7900

PrimaryBid Limited

James Deal / Kieran D'Silva

 

+ 44 (0) 203 026 4750

Further Details of the Offer

The Company highly values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Offer. The Company is therefore making the Offer available exclusively through PrimaryBid.com.

The Offer is offered under the exemptions against the need for a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority in its capacity as the UK Listing Authority. The Offer is not being made into any Restricted Jurisdiction or any other jurisdiction where it would be unlawful to do so.

There is a minimum subscription of £100 per investor under the terms of the Offer which is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a "first come first served" basis.

For further details please refer to the PrimaryBid.com website at www.PrimaryBid.com. The terms and conditions on which the Offer is made, including the procedure for application and payment for New Ordinary Shares, is available to all persons who register with PrimaryBid.com.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for New Ordinary Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for New Ordinary Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the New Ordinary Shares if they are in any doubt. 

 

 

END

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OFFBLGDRXBBDGGU
Date   Source Headline
5th Jun 202611:55 amRNSTR-1: Notification of major holdings
27th May 20267:00 amRNSIntention to delist from London Stock Exchange
20th Apr 20265:37 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSInterim Results
13th Apr 20267:00 amRNSNotice of Results
26th Mar 20267:00 amRNSShoei Litigation Conclusion
19th Mar 20267:00 amRNSStay of Shoei Litigation
23rd Feb 20267:00 amRNSShoei Litigation Update
26th Jan 20267:00 amRNSConclusion of CDX process & Directorate changes
15th Jan 20261:08 pmRNSReceipt of Litigation Proceeds
13th Jan 20264:50 pmRNSResult of AGM
12th Jan 20267:00 amRNSLitigation update
9th Dec 20257:00 amRNSBlocklisting Six-Monthly Return
8th Dec 202511:16 amRNSNotice of AGM
27th Nov 20257:00 amRNSResponse to non-infringement claim
26th Nov 20257:00 amRNSAnnual Report and Accounts
20th Nov 20257:00 amRNSLitigation outcome – Settlement agreed
18th Nov 20257:07 amRNSPreliminary Results
13th Nov 20257:00 amRNSNotice of Results
4th Nov 20257:06 amRNSExtension of Joint Development Agreement
15th Oct 20257:00 amRNS-RAwarding of Government Grant
30th Sep 20254:30 pmRNSTotal Voting Rights and Share Capital
8th Sep 20257:00 amRNSIssue of Equity and Director/PDMR Shareholdings
19th Aug 20257:00 amRNSFull Year Trading Update & Director Retirement
9th Jun 20257:00 amRNSBLOCKLISTING SIX-MONTHLY RETURN
28th Apr 202510:48 amRNSJoint Development Agreement
25th Apr 20257:00 amRNSPatent infringement lawsuit against LG
17th Apr 20253:54 pmRNSHigh Court Confirmation of Capital Reduction
15th Apr 20257:00 amRNSInterim Results & Investor Presentation
13th Mar 20257:00 amRNSNotice of Results
21st Jan 20252:20 pmRNSAnnual General Meeting – Voting Results
18th Dec 20248:26 amRNSDirector/PDMR Shareholding
13th Dec 20241:23 pmRNSResult of General Meeting
9th Dec 20247:00 amRNSBlock Listing Six Monthly Return
6th Dec 20246:30 pmRNSNotice of AGM
29th Nov 20247:00 amRNSGlass Lewis and ISS recommendations
28th Nov 20243:23 pmRNSDirector/PDMR Shareholding
28th Nov 20241:25 pmRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNS2024 Annual Report
20th Nov 20247:00 amRNSPreliminary Results
15th Nov 202411:00 amRNSPosting of Circular and Notice of General Meeting
30th Oct 20247:01 amRNSCompletion of Buyback Programme
30th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Oct 20247:00 amRNSReceipt of General Meeting Requisition Notice
23rd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Oct 20247:00 amRNSAppointment of CEO and Notice of Results
22nd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
21st Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
18th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.